DiaDeep is a biotechnology startup with a compelling mission encapsulated by its slogan, "Every patient matters, every decision counts!" The company, founded in 2022 and headquartered in France, addresses the critical decision-making challenges faced by pathologists and oncologists worldwide in the context of cancer treatment. DiaDeep's Ai Copilot applications leverage AI technology and histology slides to assist in decision-making, biomarker quantification, and prognosis prediction for various cancers like breast cancer and melanoma. The potential of DiaDeep's unique approach is evident in its critical role to provide real-time insights, ultimately empowering pathologists and oncologists and reinforcing their decision-making processes.
General Information
Get notified when DiaDeep moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track DiaDeep
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
France Market
Biotechnology
About DiaDeep
Taxonomy: Precision Medicine, Oncology, Cancer Diagnosis, Digital Pathology, Biotech, Histology, Pathologists, Biomarker Quantification, Prognosis Prediction, Medical Technology, Healthcare Innovation
No funding data available for DiaDeep yet.
Get notified when DiaDeep raises fundingDiaDeep Alternatives & Competitors
AI platform for Cancer diagnostics | Diagnostic Tools for Histopathologists and Radiologists.
How can we resolve the complexities of using precision medicine for cancer care? Trapelo knows.
1 patient - 1 tumour - 1 Oncogramme® - 1 treatment
FAQ About DiaDeep
Don't just browse. Track.
Signal Tracker monitors DiaDeep and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.